Medistim ASA (OSL:MEDI)
Norway · Delayed Price · Currency is NOK 229.00
+3.00 (1.33%)
Aug 4, 2026, 4:25 PM CET
Medistim ASA Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 209.79 | 212.09 | 179.21 | 153.87 | 152.64 | 129.49 |
Cash & Short-Term Investments | 209.79 | 212.09 | 179.21 | 153.87 | 152.64 | 129.49 |
Cash Growth | 14.36% | 18.35% | 16.47% | 0.81% | 17.88% | 80.12% |
Accounts Receivable | 104.47 | 86.39 | 68.98 | 74.3 | 101.66 | 68.63 |
Other Receivables | 17.45 | 18.11 | 20.42 | 18 | 17.26 | 10.96 |
Total Trade Receivables | 121.91 | 104.5 | 89.4 | 92.3 | 118.92 | 79.59 |
Inventory | 160.39 | 161.13 | 160.52 | 145.39 | 114.33 | 97.41 |
Total Current Assets | 492.08 | 477.72 | 429.13 | 391.57 | 385.89 | 306.5 |
Net Property, Plant & Equipment | 88.1 | 79.39 | 71.78 | 57.31 | 51.31 | 58.86 |
Other Intangible Assets | 101.7 | 86.1 | 60.72 | 45.38 | 36.07 | 30.17 |
Other Long-Term Assets | - | 17.4 | 13.34 | 11.47 | 9.38 | 7.72 |
Total Assets | 681.89 | 660.6 | 574.97 | 505.72 | 482.66 | 403.24 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | 26.63 | 17.73 | 25.08 | 24.47 | 13.21 |
Current Portion of Leases | - | 11.59 | 9.31 | 8.38 | 7.09 | 7.11 |
Other Current Liabilities | - | 104.99 | 80.33 | 60.82 | 68.27 | 57.29 |
Total Current Liabilities | 129.64 | 143.21 | 107.37 | 94.28 | 99.82 | 77.6 |
Long-Term Leases | 34.6 | 37.68 | 25.06 | 9.26 | 10.02 | 17.08 |
Other Long-Term Liabilities | 10.9 | 11.31 | 5.93 | 4.23 | 5.13 | 2.51 |
Total Long-Term Liabilities | 45.5 | 48.99 | 30.99 | 13.49 | 15.15 | 19.59 |
Total Liabilities | 175.14 | 192.19 | 138.36 | 107.78 | 114.97 | 97.19 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 |
Treasury Stock | - | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
Additional Paid-in Capital | 44.17 | 72.74 | 67.66 | 66.6 | 60.59 | 55.2 |
Accumulated Other Comprehensive Income | - | 22.28 | 35.58 | 19.39 | 16.8 | 6.14 |
Retained Earnings | 457.99 | 368.82 | 328.8 | 307.38 | 285.74 | 240.16 |
Total Common Shareholders' Equity | 506.74 | 468.41 | 436.61 | 397.94 | 367.69 | 306.05 |
Shareholders' Equity | 506.74 | 468.41 | 436.61 | 397.94 | 367.69 | 306.05 |
Total Liabilities & Equity | 681.89 | 660.6 | 574.97 | 505.72 | 482.66 | 403.24 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 34.6 | 49.27 | 34.36 | 17.64 | 17.11 | 24.19 |
Net Cash (Debt) | 175.19 | 162.82 | 144.85 | 136.23 | 135.54 | 105.3 |
Net Cash Growth | 11.39% | 12.41% | 6.33% | 0.51% | 28.72% | 221.24% |
Net Cash Per Share | 9.59 | 8.91 | 7.91 | 7.45 | 7.42 | 5.77 |
Book Value | 506.74 | 468.41 | 436.61 | 397.94 | 367.69 | 306.05 |
Book Value Per Share | 27.73 | 25.63 | 23.84 | 21.75 | 20.12 | 16.77 |
Tangible Book Value | 405.04 | 382.31 | 375.89 | 352.57 | 331.62 | 275.88 |
Tangible Book Value Per Share | 22.17 | 20.92 | 20.52 | 19.27 | 18.14 | 15.12 |